SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ampio Pharmaceuticals, Inc.

NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces it has commenced an investigation of Ampio Pharmaceuticals, Inc. ("Ampio" or "the Company") AMPE concerning possible violations of federal securities laws.

On August 7, 2018, Ampio filed a Form 8-K with the U.S. Securities and Exchange Commission providing an update on the U.S. Food and Drug Administration's review of the AP-003-A and AP-003-C trials. Ampio disclosed that it had met with the FDA in July and received a response letter, notifying the Company that the AP-003-A study alone "does not appear to provide sufficient evidence of effectiveness to support" its Biologics License Application. Following this news, shares of Ampio were down  more than 78% on intraday trading on August 8, 2018.  To obtain additional information, go to:

http://www.zlk.com/pslra-d/ampio-pharmaceuticals-inc

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:   
Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com